StockData
Amgen Inc logo

Amgen Inc (AMGN) stock

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3026% above fair value
$462.32−3.35 (-0.72%)

Close on Nov 16, 2026Market cap $249.95BP/E 26.8Yield 2.09%

Amgen total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Amgen's total debt was $54.01B at Sep 30, 2026. For fiscal 2025 it was $54.60B, down 9.1% from the year before. Over ten years it grew 5.7% a year on average. The highest annual figure on record is $64.61B in fiscal 2023.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$54.60B-9.1%
FY2024Dec 31, 2024$60.10B-7.0%
FY2023Dec 31, 2023$64.61B+65.9%
FY2022Dec 31, 2022$38.95B+16.9%
FY2021Dec 31, 2021$33.31B+1.0%
FY2020Dec 31, 2020$32.99B+10.3%
FY2019Dec 31, 2019$29.90B-11.9%
FY2018Dec 31, 2018$33.93B-4.0%
FY2017Dec 31, 2017$35.34B+2.2%
FY2016Dec 31, 2016$34.60B+10.1%
FY2015Dec 31, 2015$31.43B+2.3%
FY2014Dec 31, 2014$30.72B-4.4%
FY2013Dec 31, 2013$32.13B+33.7%
FY2012Dec 31, 2012$24.03B+12.6%
FY2011Dec 31, 2011$21.34B+96.3%
FY2010Dec 31, 2010$10.87B+2.6%
FY2009Dec 31, 2009$10.60B+158.9%
FY2008Dec 31, 2008$4.10B–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$54.01B-1.1%
Q2 FY2026Jun 30, 2026$57.30B+2.0%
Q1 FY2026Mar 31, 2026$57.32B-0.1%
Q4 FY2025Dec 31, 2025$54.60B-9.1%
Q3 FY2025Sep 30, 2025$54.59B-9.6%
Q2 FY2025Jun 30, 2025$56.20B-10.3%
Q1 FY2025Mar 31, 2025$57.38B-10.4%
Q4 FY2024Dec 31, 2024$60.10B-7.0%
Q3 FY2024Sep 30, 2024$60.40B-0.1%
Q2 FY2024Jun 30, 2024$62.65B+1.8%
Q1 FY2024Mar 31, 2024$64.02B+3.9%
Q4 FY2023Dec 31, 2023$64.61B+65.9%
Q3 FY2023Sep 30, 2023$60.47B+56.2%
Q2 FY2023Jun 30, 2023$61.54B+68.5%
Q1 FY2023Mar 31, 2023$61.60B+67.1%
Q4 FY2022Dec 31, 2022$38.95B+16.9%
Q3 FY2022Sep 30, 2022$38.70B+3.0%
Q2 FY2022Jun 30, 2022$36.52B+11.7%
Q1 FY2022Mar 31, 2022$36.85B+11.7%
Q4 FY2021Dec 31, 2021$33.31B-2.9%
Q3 FY2021Sep 30, 2021$37.58B+9.8%
Q1 FY2021Mar 31, 2021$32.69B+2.6%
Q4 FY2020Dec 31, 2020$32.99B+10.3%
Q3 FY2020Sep 30, 2020$34.29B+12.0%
Q2 FY2020Jun 30, 2020$34.22B+3.6%
Q1 FY2020Mar 31, 2020$31.85B-6.1%
Q4 FY2019Dec 31, 2019$29.90B-13.1%
Q2 FY2019Jun 30, 2019$30.61B-11.3%
Q1 FY2019Mar 31, 2019$33.02B-7.1%
Q4 FY2018Dec 31, 2018$33.93B-4.0%
Q3 FY2018Sep 30, 2018$34.43B-3.8%
Q2 FY2018Jun 30, 2018$34.50B-1.6%
Q1 FY2018Mar 31, 2018$35.54B+4.3%
Q4 FY2017Dec 31, 2017$35.34B+2.2%
Q3 FY2017Sep 30, 2017$35.78B+1.3%
Q2 FY2017Jun 30, 2017$35.06B+5.5%
Q1 FY2017Mar 31, 2017$34.09B–
Q4 FY2016Dec 31, 2016$34.60B–
Q3 FY2016Sep 30, 2016$35.32B–
Q2 FY2016Jun 30, 2016$33.22B–

More Amgen figures

See a number that looks wrong?